Related Experiment Video
Updated: Jun 12, 2026
06:52
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
CDKN1C (p57KIP2) mRNA expression in human retinoblastomas.
Jagadeesan Madhavan1, Kandalam Mallikarjuna, Khetan Vikas
1SN ONGC Department of Genetics & Molecular Biology, Vision Research Foundation, Sankara Nethralaya, Tamil Nadu, India. jmadhavan2002@yahoo.co.in
Ophthalmic Genetics
|June 23, 2010
Summary
Cyclin-dependent kinase inhibitor 1C (CDKN1C) mRNA levels are frequently elevated in retinoblastoma (RB) tumors. This study quantified CDKN1C mRNA in RB tumors but found no correlation with disease phenotype.
Area of Science:
- Oncology
- Molecular Biology
- Ophthalmology
Background:
- Retinoblastoma (RB) is the most common primary intraocular malignancy in children.
- Understanding the molecular mechanisms underlying RB development and progression is crucial for improving treatment outcomes.
Purpose of the Study:
- To quantify cyclin-dependent kinase inhibitor 1C (CDKN1C or p57KIP2) mRNA levels in human retinoblastoma tumors.
- To investigate the association between CDKN1C mRNA expression and retinoblastoma disease phenotype.
Main Methods:
- CDKN1C mRNA expression was measured using real-time PCR in 55 retinoblastoma tumors, 3 retinoblastoma cell lines, and 12 control retinas.
- Immunohistochemistry was employed to confirm the localization of CDKN1C protein.
- Correlation analysis was performed between tumor CDKN1C expression levels and clinical phenotype.
Main Results:
- Elevated CDKN1C mRNA levels were observed in 53 out of 55 retinoblastoma tumors compared to adult retina controls.
- CDKN1C mRNA levels in tumors did not significantly differ from fetal retinal controls or retinoblastoma cell lines.
- Immunohistochemistry showed heterogeneous CDKN1C protein staining, predominantly nuclear, in tumor cells.
- No correlation was found between CDKN1C mRNA expression levels and retinoblastoma tumor phenotype.
Conclusions:
- High expression of CDKN1C is a common feature in retinoblastoma.
- The functional significance of elevated CDKN1C expression in RB requires further investigation.
- Potential roles include a protective response to transformation, a selective advantage for tumor cells, or a marker of cell proliferation.
Related Concept Videos
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.